|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.69 USD | +0.49% |
|
+14.29% | +92.12% |
| 05-09 | Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating | MT |
| 05-08 | Transcript : Tarsus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Tarsus Pharmaceuticals, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 17.45 million compared to USD 25.82 million a year ago. Net loss was USD 135.89 million compared to USD 62.09 million a year ago.
Basic loss per share from continuing operations was USD 4.62 compared to USD 2.52 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +92.12% | 1.45B | |
| +33.19% | 709B | |
| +30.77% | 595B | |
| -2.05% | 367B | |
| +20.16% | 334B | |
| +5.30% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.31% | 171B |
TARSUS PHARMACEUTICALS, INC. 
